NCT07734272Not yet recruiting
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
STANDARDIZEd Documentation and Assessments for Polycythemia Vera (STANDARDIZE-PV): A Quality Improvement Initiative
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative ropeginterferon alfa-2b titration service is feasible, acceptable, and appropriate for clinicians who manage PV.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 24 Jul 2026
- Start date
- 5 Aug 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT07734272
What you commit to
- Study type: Interventional
- Planned participants: 32
- From 5 Aug 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Clinicians who do not have an outpatient hematology or medical oncology clinic within Mass General Brigham.
- Clinicians who do not utilize the EPIC electronic medical record (EMR) System as their method of patient progress note documentation.
Who the study is looking for
- \- Hematologists and medical oncologists within the Mass General Brigham network sites who treat at least one patient with PV in their outpatient clinic.
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.